AR038632A1 - Composicion farmaceutica - Google Patents

Composicion farmaceutica

Info

Publication number
AR038632A1
AR038632A1 ARP030100673A ARP030100673A AR038632A1 AR 038632 A1 AR038632 A1 AR 038632A1 AR P030100673 A ARP030100673 A AR P030100673A AR P030100673 A ARP030100673 A AR P030100673A AR 038632 A1 AR038632 A1 AR 038632A1
Authority
AR
Argentina
Prior art keywords
substance
pharmaceutical composition
ocif
prostaglandins
group
Prior art date
Application number
ARP030100673A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of AR038632A1 publication Critical patent/AR038632A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica que contiene: (i) un complejo que comprende por lo menos una sustancia seleccionada del grupo que consiste de factor inhibidor de osteoclastogénesis (OCIF), análogos del mismo y variantes del mismo, el cual se une a por lo menos una sustancia seleccionada del grupo que consiste de polisacáridos y derivados de los mismos; y (ii) una sustancia que suprime la producción de prostaglandinas y/o una sustancia que compite con una acción biológica de prostaglandinas, muestra retención prolongada de dicho OCIF, análogo del mismo o variante del mismo en la corriente sanguínea después de su administración, así como actividad farmacológica mejorada, haciéndola útil en el tratamiento y profilaxis de enfermedades metabólicas óseas.
ARP030100673A 2002-03-01 2003-02-28 Composicion farmaceutica AR038632A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002055356 2002-03-01

Publications (1)

Publication Number Publication Date
AR038632A1 true AR038632A1 (es) 2005-01-19

Family

ID=27784607

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100673A AR038632A1 (es) 2002-03-01 2003-02-28 Composicion farmaceutica

Country Status (7)

Country Link
US (2) US20030216297A1 (es)
EP (1) EP1482978A1 (es)
AR (1) AR038632A1 (es)
AU (1) AU2003208621A1 (es)
PA (1) PA8568001A1 (es)
TW (1) TW200303757A (es)
WO (1) WO2003074084A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
EP1127578A4 (en) 1998-10-28 2004-12-15 Sankyo Co MEDICINE FOR BONE METABOLIC DEVIATIONS
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
EP1482978A1 (en) * 2002-03-01 2004-12-08 Sankyo Company, Limited Pharmaceutical composition comprising osteoclastogenesis inhibitory factor
WO2005027918A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor
ES2901421T3 (es) * 2017-04-11 2022-03-22 Straumann Holding Ag Implante dental
CN113842464B (zh) * 2021-09-24 2023-07-04 江苏贝美医疗科技有限公司 一种类风湿因子吸附材料及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
KR100547395B1 (ko) * 1997-09-24 2006-02-01 산쿄 가부시키가이샤 골대사이상증의 진단방법
AU4061899A (en) * 1998-06-15 2000-01-05 Takeda Chemical Industries Ltd. Thienodipyridine derivatives, production and use thereof
EP1127578A4 (en) * 1998-10-28 2004-12-15 Sankyo Co MEDICINE FOR BONE METABOLIC DEVIATIONS
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
MXPA02006027A (es) * 1999-12-16 2002-12-05 Amgen Inc Moleculas tipo osteoprotegerina/receptor del factor de necrosis de tumor y usos de las mismas.
CZ20022231A3 (cs) * 2001-06-29 2003-02-12 Sankyo Company Limited Komplex skládající se z osteoklastogenezi inhibujícího faktoru a polysacharidu
EP1482978A1 (en) * 2002-03-01 2004-12-08 Sankyo Company, Limited Pharmaceutical composition comprising osteoclastogenesis inhibitory factor

Also Published As

Publication number Publication date
US20030181418A1 (en) 2003-09-25
WO2003074084A1 (en) 2003-09-12
TW200303757A (en) 2003-09-16
EP1482978A1 (en) 2004-12-08
US20030216297A1 (en) 2003-11-20
PA8568001A1 (es) 2003-11-12
AU2003208621A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
UY27939A1 (es) Compuestos
GT200900154A (es) Derivados de 2,3-dihidroimidozo [1,2-c] quinizolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
UY28945A1 (es) Derivados de pirrolopiridina
PE20060594A1 (es) Composicion farmaceutica que contiene un agonista de ppar
AR109263A2 (es) Composición que comprende moxidectina
AR038605A1 (es) Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
AR050418A1 (es) Dosificacion fija de anticuerpos her
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
AR056806A1 (es) Moleculas quimericas de anticuerpo rankl- pth/ pthrp
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2009088838A3 (en) Triarylmethane analogs and their use in treating cancers
EA000626B3 (ru) Синергические комбинации зидовудина, 1592u89 и зтс или ftc
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
CO2022011728A2 (es) Composiciones y usos de glp-1
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
CO6270306A2 (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo
AR038141A1 (es) Composiciones farmaceuticas estables que comprenden inhibidor(es) de ace
AR038632A1 (es) Composicion farmaceutica
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
PE20070711A1 (es) Derivados de piperazina utiles como antagonistas de ccr5
ECSP045110A (es) Composiciones de la preparación que contiene un compuesto fisiologicamente activo de acidos inestables y procesos para su producción
AR033390A1 (es) Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
AR034716A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
AR044675A1 (es) Metodo para el tratamiento de la esquizofrenia en un paciente con sobrepeso

Legal Events

Date Code Title Description
FB Suspension of granting procedure